Oncology – Skin
RCT: Sirolimus plus prednisolone vs. sirolimus monotherapy for kaposiform hemangioendothelioma.
18 Jan, 2022 | 09:08h | UTCSirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link to abstract – $ for full-text)
RCT: In patients with untreated advanced melanoma, treatment with Relatlimab plus Nivolumab was associated with increased median progression-free survival compared with Nivolumab alone (10.1 months vs. 4.6 months).
12 Jan, 2022 | 08:43h | UTCRelatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to PFS than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. https://t.co/idtOgksg74 pic.twitter.com/vx1W9O4Dh6
— NEJM (@NEJM) January 5, 2022
RCT: Long-term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone vs. Ipilimumab in patients with advanced melanoma.
5 Dec, 2021 | 23:07h | UTCEditorial: CheckMate-067: Raising the Bar for the Next Decade in Oncology – Journal of Clinical Oncology
Original Study: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma
Guideline on Cutaneous Angiosarcomas – Update 2021.
26 Nov, 2021 | 10:00h | UTCS1-Guideline Cutaneous Angiosarcomas – Update 2021 – Journal of the German Society of Dermatology
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab.
16 Nov, 2021 | 08:14h | UTCLong-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Original Study: Study: Combination Immunotherapy for Melanoma Brain Metastases
RCT: Overall survival benefit with Tebentafusp in metastatic uveal melanoma.
28 Sep, 2021 | 09:03h | UTC
Commentary on Twitter
Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. https://t.co/HnSdWItKIp pic.twitter.com/qu4huRn3Mu
— NEJM (@NEJM) September 27, 2021
Viewpoint: Sentinel lymph node biopsy in cutaneous melanoma—where do we stand?
22 Aug, 2021 | 22:16h | UTCSentinel Lymph Node Biopsy in Cutaneous Melanoma—Where Do We Stand? – JAMA Dermatology (free for a limited period)
US Report: Death rates are declining for many common cancers, including lung cancer and melanoma.
15 Jul, 2021 | 09:11h | UTCCommentaries: Death rates are declining for many common cancers in the U.S., report finds – STAT AND Annual report to the nation: Rapid decrease in lung cancer and melanoma deaths – American Cancer Society
Viewpoint | Active surveillance as a management option for low-risk basal cell carcinoma.
15 Jun, 2021 | 08:49h | UTC
An epidemic of overdiagnosis: Melanoma diagnoses sky rocket
20 Jan, 2021 | 01:30h | UTCAn epidemic of overdiagnosis: Melanoma diagnoses sky rocket – Brigham and Women’s Hospital AND Does Screening for Skin Cancer Result in Melanoma Overdiagnosis? – Univadis
Original study: The Rapid Rise in Cutaneous Melanoma Diagnoses ($)
Related: Overdiagnosis: what it is and what it isn’t – BMJ Evidence Based Medicine (free) AND Overdiagnosis across medical disciplines: a scoping review – The BMJ Open (free) AND Too much medical care: bad for you, bad for health care systems – STAT News (free) AND Screening: How overdiagnosis and other harms can undermine the benefits – Health News Review (free) AND Overdiagnosis: causes and consequences in primary health care – Canadian Family Physician (free) AND Five warning signs of overdiagnosis – The Conversation (free) AND What is overdiagnosed cancer? And why does it matter? – Croakey (free) AND Blame rising cancer overdiagnosis on ‘irrational exuberance’ for early detection – STAT (free) AND Preventing overdiagnosis and the harms of too much sport and exercise medicine – British Journal of Sports Medicine (free)